Filing Details

Accession Number:
0001127602-20-018080
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-28 18:05:09
Reporting Period:
2020-05-26
Accepted Time:
2020-05-28 18:05:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1682852 Moderna Inc. MRNA Biological Products, (No Disgnostic Substances) (2836) 813467528
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1690927 Zvi Tal Zaks C/O Moderna, Inc.
200 Technology Square
Cambridge MA 02139
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-26 42,570 $14.22 42,570 No 4 M Direct
Common Stock Acquisiton 2020-05-26 82,474 $12.21 125,044 No 4 M Direct
Common Stock Disposition 2020-05-26 125,044 $66.54 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-05-26 82,474 $0.00 82,474 $12.21
Common Stock Stock Option (Right to Buy) Disposition 2020-05-26 42,570 $0.00 42,570 $14.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
263,760 2027-10-03 No 4 M Direct
117,980 2028-02-28 No 4 M Direct
Footnotes
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
  2. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
  3. 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.